| Literature DB >> 31614667 |
Juliette Cholet1, Caroline Decombat2, Marjolaine Vareille-Delarbre3, Maël Gainche4, Alexandre Berry5, François Senejoux6, Isabelle Ripoche7, Laetitia Delort8, Marion Vermerie9, Didier Fraisse10, Catherine Felgines11, Edwige Ranouille12, Jean-Yves Berthon13, Julien Priam14, Etienne Saunier15, Albert Tourrette16, Yves Troin17, Gilles Thebaud18, Pierre Chalard19, Florence Caldefie-Chezet20.
Abstract
BACKGROUND: Some Bupleurum species, such as the Bupleurum chinense DC. or the Bupleurum scorzonerifolium Willd have been extensively studied (especially their roots) for the treatment of inflammation. In contrast, only compounds extracted from the aerial parts of Bupleurum rotundifolium have been studied and showed anti-inflammatory or antiproliferative activities. This study was conducted to investigate the antioxidant, anti-inflammatory, and immunomodulatory effects of Bupleurum rotundifolium roots.Entities:
Keywords: Bupleurum rotundifolium; PBMCs; antioxidant; cytokines; inflammation
Year: 2019 PMID: 31614667 PMCID: PMC6963863 DOI: 10.3390/medicines6040101
Source DB: PubMed Journal: Medicines (Basel) ISSN: 2305-6320
Some of the major constituents of the methanolic extract of Bupleurum rotundifolium roots.
| RT 1 (min) | [M − H]− ( | Compound |
|---|---|---|
| 3.84 | 191.0549 | Quinic acid 2 |
| 4.1 | 341.1085 | Saccharose 2 |
| 6.83 | 191.0186 | Citric acid 2 |
| 12.92 | 353.0875 | Chlorogenic acid 2 |
| 14.31 | 353.0875 | Cryptochlorogenic acid 2 |
| 15.88 | 367.1029 | 3- |
| 17.52 | 367.1030 | Feruloylquinic acid Isomer 3 |
| 18.46 | 463.0880 | Isoquercitrin 2 |
| 20.72 | 623.1614 | Narcissin 3 |
| 22.95 | 477.1035 | Isorhamnetin-3- |
1 Retention time. 2 Identification by comparison with an analytical standard. 3 Identification by comparison with publication.
Radical scavenging capacity, iron (II)-chelating activity, and phenolic and flavonoid contents.1.
| ORAC | DPPH | Iron (II) Chelation | Flavonoid Content | Total Phenolic Content |
|---|---|---|---|---|
| 1277 ± 852 | 198 ± 8.5 | 47.3 ± 3.23 | 13.9 ± 0.2 | 47 ± 0.3 |
1 Data are expressed as the mean of triplicate ± SD. 2 TE: Trolox equivalent. 3 EDTAE: EDTA equivalent. 4 RE: Rutin equivalent. 5 GAE: Gallic acid equivalent.
Figure 1BRE concentration dependently inhibited ROS production of blood leukocytes. Cells were incubated with BRE (0, 10, 25, 50, and 100 µg/mL) and stimulated with PMA (1 µM) for (a) 30 min; (b) 1 h; and (c) 2 h. Data were shown as means ± SD; # p < 0.05 compared with Control, $ p < 0.05 compared with PMA-stimulated cells (0 µg/mL BRE). BRE: Bupleurum rotundifolium.
Figure 2BRE did not affect leukocyte viability. Cells were treated with the indicated concentrations of BRE for 2 h, and then cell viability was measured. Data were shown as means ± SD (Control = 100%); * p < 0.05 compared with Control.
Influence of BRE on PMNs chemotaxis 1.
| Migration | BRE Concentration (µg/mL) | |
|---|---|---|
| 0 | 50 | |
| SM 2 | 75 ± 22 | 31.3 ± 9 * |
| DM 3 | 90 ± 24 | 67.5 ± 7 |
| DM/SM | 1.3 ± 0.4 | 2.3 ± 0.6 * |
1 Data are expressed as mean ± SD, * p < 0.05 compared with control (0 µg/mL BRE). 2 SM: spontaneous migration toward culture media 3 DM: directed migration toward chemotactic factor (fMLP). PMNs: Polymorphonuclear neutrophils.
Figure 3BRE promoted the differentiation of THP-1 cells. Cells were incubated with BRE (50 µg/mL) and stimulated with PMA (16.2 nM) for 70 h. $ p < 0.05 compared with PMA-stimulated cells, $$ p < 0.01 compared with PMA-stimulated cells.
Figure 4BRE increased PGE2 production without LPS. Cells were incubated with BRE as indicated and stimulated with LPS (1 µg/mL) for 24 h. Data were shown as means ± SD; * p < 0.05 compared with Control (paired t-test).
BRE impacted cytokines secretions of PBMCs. Cells were incubated with BRE as indicated and stimulated with PHA (5 µg/mL) for 24 h. Data were shown as means ± SD (pg/mL); ND: not detected.
| Without PHA | PHA (5 µg/mL) | |||||
|---|---|---|---|---|---|---|
| BRE Concentration (µg/mL) | BRE Concentration (µg/mL) | |||||
| 0 | 50 | Variation 1 | 0 | 50 | Variation 1 | |
| IL-2 | 15.4 ± 11 | 4.5 ± 0.7 | NS | 327.9 ± 188 | 125.6 ± 101.3 | NS |
| IL-4 | 1.4 ± 1 | 3.5 ± 0.9 | (++) | 198.7 ± 96.6 | 112.2 ± 28.8 | NS |
| IL-10 | 14.4 ± 7.3 | 10.6 ± 6.1 | NS | 10,354.5 ± 3830 | 10,284.7 ± 1350 | NS |
| IL-5 | ND | ND | 33.9 ± 23.1 | 15.37 ± 11.9 | NS | |
| IL12p70 | 0.73 ± 0.6 | 0.24 ± 0.3 | NS | 40.73 ± 11.9 | 17.1 ± 10.5 | (−−) |
| IL-1β | 9.2 ± 9.1 | 952 ± 890 | (+) | 2548.5 ± 402.2 | 1334.7 ± 33.5 | (−−) |
| TNFα | 15.9 ± 9.2 | 715 ± 216 | (++) | 4637.2 ± 1518 | 7538.7 ± 185.5 | (++) |
| IL-8 | 535.7 ± 196 | 816 ± 5.8 | (+) | 748.9 ± 65 | 1197 ± 19 | (++) |
| MIP1α | 4.2 ± 2.7 | 204 ± 163 | (+) | 1757.8 ± 578 | 1026.1 ± 20.7 | (−) |
| MIP1β | 137 ± 107 | 3300 ± 2890 | (++) | 6400.1 ± 603.5 | 6275.6 ± 359.2 | NS |
| IL-12p70/ IL-10 | 0.05 ± 0.03 | 0.03 ± 0.05 | NS | 0.001 ± 0.0009 | 0.003 ± 0.003 | (−) |
1 (+): positive change between 0 and 50 µg/mL BRE (trend, 0.05 < p < 0.1); (++): significant positive change between 0 and 50 µg/mL BRE (p < 0.05); (−): negative change between 0 and 50 µg/mL BRE (trend, 0.05 < p < 0.1); (−−): significant negative change between 0 and 50 µg/mL BRE (p < 0.05); NS: no significant difference (t-test). PBMCs: peripheral blood mononuclear cells.
Figure 5BRE impacted cytokines secretions of PBMCs. Cells were incubated with BRE as indicated and stimulated with PHA (5 µg/mL) for 24 h. Red solid line: production of main pro- and anti-inflammatory cytokines in Control (PHA-stimulated cells, 0 µg/mL BRE). Blue solid line: production of main pro- and anti-inflammatory cytokines in supernatants of cells incubated with BRE and PHA. Data were shown as means (Control = 100%). * p < 0.05 compared with Control. Red dotted line: Control mean minus corresponding standard error mean. Blue dotted line: BRE and PHA mean plus corresponding SEM.
Figure 6BRE increased NF-κB p65 in PBMCs. Cells were incubated with BRE (0, or 50 µg/mL) and stimulated with LPS (1 µg/mL) for 1 h.